CAL
AXDX icon

Capital Advisors Ltd’s Accelerate Diagnostics AXDX Stock Holding History

Capital Advisors Ltd’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-153
Closed -$2K – 1217
2022
Q3 		$2K Hold
153
– – ﹤0.01% 806
2022
Q2 		$2K Buy
+153
New +$1.35K ﹤0.01% 646

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Capital Advisors Ltd's AXDX Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 153 shares — an estimated $2K sold.

Capital Advisors Ltd first reported a position in AXDX in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 73 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 153 Accelerate Diagnostics shares in Q4 2022, an estimated $2K.
  • Capital Advisors Ltd first reported a position in Accelerate Diagnostics in Q2 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's Accelerate Diagnostics position peaked at $2K in Q3 2022.
  • 73 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.